#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6 .
1-1	0-1	6	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Angiogenesis in Glioblastomas
2-1	4-16	Angiogenesis	abstract[2]	new[2]	coref	3-14[9_2]
2-2	17-19	in	abstract[2]	new[2]	_	_
2-3	20-33	Glioblastomas	abstract[2]|place	new[2]|new	coref	3-3

#Text=Features of glioblastomas are a high propensity to invade the surrounding tissues and extensive angiogenesis .
3-1	34-42	Features	abstract[4]	new[4]	coref	3-5[6_4]
3-2	43-45	of	abstract[4]	new[4]	_	_
3-3	46-59	glioblastomas	abstract[4]|abstract	new[4]|giv	coref	9-11
3-4	60-63	are	_	_	_	_
3-5	64-65	a	abstract[6]	giv[6]	_	_
3-6	66-70	high	abstract[6]	giv[6]	_	_
3-7	71-81	propensity	abstract[6]	giv[6]	_	_
3-8	82-84	to	_	_	_	_
3-9	85-91	invade	_	_	_	_
3-10	92-95	the	object[7]|abstract[8]	new[7]|new[8]	ana|ana	4-1[0_8]|4-1[0_8]
3-11	96-107	surrounding	object[7]|abstract[8]	new[7]|new[8]	_	_
3-12	108-115	tissues	object[7]|abstract[8]	new[7]|new[8]	_	_
3-13	116-119	and	abstract[8]	new[8]	_	_
3-14	120-129	extensive	abstract[8]|abstract[9]	new[8]|giv[9]	coref	6-1[0_9]
3-15	130-142	angiogenesis	abstract[8]|abstract[9]	new[8]|giv[9]	_	_
3-16	143-144	.	_	_	_	_

#Text=They are characterized by a pathological vascular system with a dense network of winding vessels of different diameters , increased permeability , and with abnormally thickened basement membranes .
4-1	145-149	They	abstract	giv	_	_
4-2	150-153	are	_	_	_	_
4-3	154-167	characterized	_	_	_	_
4-4	168-170	by	_	_	_	_
4-5	171-172	a	abstract[11]	new[11]	_	_
4-6	173-185	pathological	abstract[11]	new[11]	_	_
4-7	186-194	vascular	abstract[11]	new[11]	_	_
4-8	195-201	system	abstract[11]	new[11]	_	_
4-9	202-206	with	_	_	_	_
4-10	207-208	a	abstract[12]	new[12]	coref	13-13[0_12]
4-11	209-214	dense	abstract[12]	new[12]	_	_
4-12	215-222	network	abstract[12]	new[12]	_	_
4-13	223-225	of	_	_	_	_
4-14	226-233	winding	_	_	_	_
4-15	234-241	vessels	object[13]	new[13]	coref	6-15[32_13]
4-16	242-244	of	object[13]	new[13]	_	_
4-17	245-254	different	object[13]|quantity[14]	new[13]|new[14]	_	_
4-18	255-264	diameters	object[13]|quantity[14]	new[13]|new[14]	_	_
4-19	265-266	,	object[13]	new[13]	_	_
4-20	267-276	increased	object[13]|abstract[15]	new[13]|new[15]	_	_
4-21	277-289	permeability	object[13]|abstract[15]	new[13]|new[15]	_	_
4-22	290-291	,	object[13]	new[13]	_	_
4-23	292-295	and	object[13]	new[13]	_	_
4-24	296-300	with	object[13]	new[13]	_	_
4-25	301-311	abnormally	object[13]|object[17]	new[13]|new[17]	_	_
4-26	312-321	thickened	object[13]|object[17]	new[13]|new[17]	_	_
4-27	322-330	basement	object[13]|place|object[17]	new[13]|new|new[17]	coref	8-26
4-28	331-340	membranes	object[13]|object[17]	new[13]|new[17]	_	_
4-29	341-342	.	_	_	_	_

#Text=These properties are often the cause of relapses and therapy failures because they hinder tumor access to cytotoxic chemotherapy .
5-1	343-348	These	abstract[18]	new[18]	coref	5-4[19_18]
5-2	349-359	properties	abstract[18]	new[18]	_	_
5-3	360-363	are	_	_	_	_
5-4	364-369	often	abstract[19]	giv[19]	ana	5-13[0_19]
5-5	370-373	the	abstract[19]	giv[19]	_	_
5-6	374-379	cause	abstract[19]	giv[19]	_	_
5-7	380-382	of	abstract[19]	giv[19]	_	_
5-8	383-391	relapses	abstract[19]|event	giv[19]|new	_	_
5-9	392-395	and	abstract[19]	giv[19]	_	_
5-10	396-403	therapy	abstract[19]|event|event[22]	giv[19]|new|new[22]	_	_
5-11	404-412	failures	abstract[19]|event[22]	giv[19]|new[22]	_	_
5-12	413-420	because	_	_	_	_
5-13	421-425	they	abstract	giv	_	_
5-14	426-432	hinder	_	_	_	_
5-15	433-438	tumor	abstract|abstract[25]	new|new[25]	coref|coref	6-7[30_0]|6-7[30_0]
5-16	439-445	access	abstract[25]	new[25]	_	_
5-17	446-448	to	abstract[25]	new[25]	_	_
5-18	449-458	cytotoxic	abstract[25]|place|substance[27]	new[25]|new|new[27]	_	_
5-19	459-471	chemotherapy	abstract[25]|substance[27]	new[25]|new[27]	_	_
5-20	472-473	.	_	_	_	_

#Text=Angiogenesis caused by the presence of a tumor is defined as the formation of new blood vessels based on existing ones , which can be visualized using ultra-high-field magnetic resonance angiography .
6-1	474-486	Angiogenesis	abstract	giv	coref	9-9[54_0]
6-2	487-493	caused	_	_	_	_
6-3	494-496	by	_	_	_	_
6-4	497-500	the	abstract[29]	new[29]	_	_
6-5	501-509	presence	abstract[29]	new[29]	_	_
6-6	510-512	of	abstract[29]	new[29]	_	_
6-7	513-514	a	abstract[29]|abstract[30]	new[29]|giv[30]	_	_
6-8	515-520	tumor	abstract[29]|abstract[30]	new[29]|giv[30]	_	_
6-9	521-523	is	_	_	_	_
6-10	524-531	defined	_	_	_	_
6-11	532-534	as	_	_	_	_
6-12	535-538	the	_	_	_	_
6-13	539-548	formation	_	_	_	_
6-14	549-551	of	_	_	_	_
6-15	552-555	new	object[32]	giv[32]	coref	8-42[51_32]
6-16	556-561	blood	substance|object[32]	new|giv[32]	_	_
6-17	562-569	vessels	object[32]	giv[32]	_	_
6-18	570-575	based	_	_	_	_
6-19	576-578	on	_	_	_	_
6-20	579-587	existing	_	_	_	_
6-21	588-592	ones	object	new	_	_
6-22	593-594	,	_	_	_	_
6-23	595-600	which	_	_	_	_
6-24	601-604	can	_	_	_	_
6-25	605-607	be	_	_	_	_
6-26	608-618	visualized	_	_	_	_
6-27	619-624	using	_	_	_	_
6-28	625-641	ultra-high-field	object[35]	new[35]	_	_
6-29	642-650	magnetic	object[35]	new[35]	_	_
6-30	651-660	resonance	abstract|object[35]	new|new[35]	_	_
6-31	661-672	angiography	object[35]	new[35]	_	_
6-32	673-674	.	_	_	_	_

#Text=The mechanism of this process is very complex .
7-1	675-678	The	abstract[36]	new[36]	coref	16-9[103_36]
7-2	679-688	mechanism	abstract[36]	new[36]	_	_
7-3	689-691	of	abstract[36]	new[36]	_	_
7-4	692-696	this	abstract[36]|abstract[37]	new[36]|new[37]	_	_
7-5	697-704	process	abstract[36]|abstract[37]	new[36]|new[37]	_	_
7-6	705-707	is	_	_	_	_
7-7	708-712	very	_	_	_	_
7-8	713-720	complex	_	_	_	_
7-9	721-722	.	_	_	_	_

#Text=In GBM , the development of pathological vasculature is based on changes in adhesion molecules on the endothelial surface , the presence of an erratic basement membrane , a decrease in pericyte coverage , and a weaker binding of astrocytes to blood vessels .
8-1	723-725	In	_	_	_	_
8-2	726-729	GBM	place	new	coref	29-15
8-3	730-731	,	_	_	_	_
8-4	732-735	the	event[39]	new[39]	_	_
8-5	736-747	development	event[39]	new[39]	_	_
8-6	748-750	of	event[39]	new[39]	_	_
8-7	751-763	pathological	event[39]|object[40]	new[39]|new[40]	_	_
8-8	764-775	vasculature	event[39]|object[40]	new[39]|new[40]	_	_
8-9	776-778	is	_	_	_	_
8-10	779-784	based	_	_	_	_
8-11	785-787	on	_	_	_	_
8-12	788-795	changes	abstract[41]	new[41]	_	_
8-13	796-798	in	abstract[41]	new[41]	_	_
8-14	799-807	adhesion	abstract[41]|object[42]	new[41]|new[42]	_	_
8-15	808-817	molecules	abstract[41]|object[42]	new[41]|new[42]	_	_
8-16	818-820	on	abstract[41]|object[42]	new[41]|new[42]	_	_
8-17	821-824	the	abstract[41]|object[42]|place[43]	new[41]|new[42]|new[43]	_	_
8-18	825-836	endothelial	abstract[41]|object[42]|place[43]	new[41]|new[42]|new[43]	_	_
8-19	837-844	surface	abstract[41]|object[42]|place[43]	new[41]|new[42]|new[43]	_	_
8-20	845-846	,	_	_	_	_
8-21	847-850	the	abstract[44]	new[44]	_	_
8-22	851-859	presence	abstract[44]	new[44]	_	_
8-23	860-862	of	abstract[44]	new[44]	_	_
8-24	863-865	an	abstract[44]|object[46]	new[44]|new[46]	_	_
8-25	866-873	erratic	abstract[44]|object[46]	new[44]|new[46]	_	_
8-26	874-882	basement	abstract[44]|place|object[46]	new[44]|giv|new[46]	_	_
8-27	883-891	membrane	abstract[44]|object[46]	new[44]|new[46]	_	_
8-28	892-893	,	_	_	_	_
8-29	894-895	a	abstract[47]	new[47]	_	_
8-30	896-904	decrease	abstract[47]	new[47]	_	_
8-31	905-907	in	abstract[47]	new[47]	_	_
8-32	908-916	pericyte	abstract[47]|abstract[48]	new[47]|new[48]	_	_
8-33	917-925	coverage	abstract[47]|abstract[48]	new[47]|new[48]	_	_
8-34	926-927	,	_	_	_	_
8-35	928-931	and	_	_	_	_
8-36	932-933	a	object[49]	new[49]	_	_
8-37	934-940	weaker	object[49]	new[49]	_	_
8-38	941-948	binding	object[49]	new[49]	_	_
8-39	949-951	of	object[49]	new[49]	_	_
8-40	952-962	astrocytes	object[49]|abstract[50]	new[49]|new[50]	_	_
8-41	963-965	to	object[49]|abstract[50]	new[49]|new[50]	_	_
8-42	966-971	blood	object[49]|abstract[50]|object[51]	new[49]|new[50]|giv[51]	coref	9-32[63_51]
8-43	972-979	vessels	object[49]|abstract[50]|object[51]	new[49]|new[50]|giv[51]	_	_
8-44	980-981	.	_	_	_	_

#Text=A common element for the large invasiveness and angiogenesis of glioblastomas is the loss of tumor cell boundaries with the surrounding microenvironment consisting of brain tissue , subarachnoid space , and blood vessels .
9-1	982-983	A	abstract[52]	new[52]	coref	9-13[56_52]
9-2	984-990	common	abstract[52]	new[52]	_	_
9-3	991-998	element	abstract[52]	new[52]	_	_
9-4	999-1002	for	abstract[52]	new[52]	_	_
9-5	1003-1006	the	abstract[52]|abstract[53]	new[52]|new[53]	coref	27-14[0_53]
9-6	1007-1012	large	abstract[52]|abstract[53]	new[52]|new[53]	_	_
9-7	1013-1025	invasiveness	abstract[52]|abstract[53]	new[52]|new[53]	_	_
9-8	1026-1029	and	abstract[52]	new[52]	_	_
9-9	1030-1042	angiogenesis	abstract[52]|abstract[54]	new[52]|giv[54]	coref	10-1[0_54]
9-10	1043-1045	of	abstract[52]|abstract[54]	new[52]|giv[54]	_	_
9-11	1046-1059	glioblastomas	abstract[52]|abstract[54]|object	new[52]|giv[54]|giv	_	_
9-12	1060-1062	is	_	_	_	_
9-13	1063-1066	the	abstract[56]	giv[56]	_	_
9-14	1067-1071	loss	abstract[56]	giv[56]	_	_
9-15	1072-1074	of	abstract[56]	giv[56]	_	_
9-16	1075-1080	tumor	abstract[56]|place[58]	giv[56]|new[58]	_	_
9-17	1081-1085	cell	abstract[56]|place|place[58]	giv[56]|new|new[58]	coref	15-12
9-18	1086-1096	boundaries	abstract[56]|place[58]	giv[56]|new[58]	_	_
9-19	1097-1101	with	abstract[56]|place[58]	giv[56]|new[58]	_	_
9-20	1102-1105	the	abstract[56]|place[58]|place[59]	giv[56]|new[58]|new[59]	_	_
9-21	1106-1117	surrounding	abstract[56]|place[58]|place[59]	giv[56]|new[58]|new[59]	_	_
9-22	1118-1134	microenvironment	abstract[56]|place[58]|place[59]	giv[56]|new[58]|new[59]	_	_
9-23	1135-1145	consisting	_	_	_	_
9-24	1146-1148	of	_	_	_	_
9-25	1149-1154	brain	object|object[61]	new|new[61]	_	_
9-26	1155-1161	tissue	object[61]	new[61]	_	_
9-27	1162-1163	,	_	_	_	_
9-28	1164-1176	subarachnoid	place[62]	new[62]	_	_
9-29	1177-1182	space	place[62]	new[62]	_	_
9-30	1183-1184	,	_	_	_	_
9-31	1185-1188	and	_	_	_	_
9-32	1189-1194	blood	object[63]	giv[63]	_	_
9-33	1195-1202	vessels	object[63]	giv[63]	_	_
9-34	1203-1204	.	_	_	_	_

#Text=Angiogenesis occurs under the influence of various mechanisms , which we divide into hypoxia-dependent and hypoxia-independent .
10-1	1205-1217	Angiogenesis	substance	giv	coref	14-15
10-2	1218-1224	occurs	_	_	_	_
10-3	1225-1230	under	_	_	_	_
10-4	1231-1234	the	abstract[65]	new[65]	_	_
10-5	1235-1244	influence	abstract[65]	new[65]	_	_
10-6	1245-1247	of	abstract[65]	new[65]	_	_
10-7	1248-1255	various	abstract[65]|abstract[66]	new[65]|new[66]	_	_
10-8	1256-1266	mechanisms	abstract[65]|abstract[66]	new[65]|new[66]	_	_
10-9	1267-1268	,	_	_	_	_
10-10	1269-1274	which	_	_	_	_
10-11	1275-1277	we	person	acc	_	_
10-12	1278-1284	divide	_	_	_	_
10-13	1285-1289	into	_	_	_	_
10-14	1290-1307	hypoxia-dependent	abstract	new	_	_
10-15	1308-1311	and	_	_	_	_
10-16	1312-1331	hypoxia-independent	abstract	new	_	_
10-17	1332-1333	.	_	_	_	_

#Text=Hypoxia has been proven to inactivate prolyl hydroxylases .
11-1	1334-1341	Hypoxia	substance	new	ana	12-1
11-2	1342-1345	has	_	_	_	_
11-3	1346-1350	been	_	_	_	_
11-4	1351-1357	proven	_	_	_	_
11-5	1358-1360	to	_	_	_	_
11-6	1361-1371	inactivate	_	_	_	_
11-7	1372-1378	prolyl	abstract|substance[72]	new|new[72]	_	_
11-8	1379-1391	hydroxylases	substance[72]	new[72]	_	_
11-9	1392-1393	.	_	_	_	_

#Text=This increases the level of hypoxia-inducible factor-1α ( HIF-1α ) , causing the release of vascular endothelial growth factor ( VEGF ) by glioma cells affected by hypoxia .
12-1	1394-1398	This	substance	giv	coref	12-28
12-2	1399-1408	increases	_	_	_	_
12-3	1409-1412	the	abstract[74]	new[74]	_	_
12-4	1413-1418	level	abstract[74]	new[74]	_	_
12-5	1419-1421	of	abstract[74]	new[74]	_	_
12-6	1422-1439	hypoxia-inducible	abstract[74]|abstract[75]	new[74]|new[75]	appos	12-9[0_75]
12-7	1440-1449	factor-1α	abstract[74]|abstract[75]	new[74]|new[75]	_	_
12-8	1450-1451	(	_	_	_	_
12-9	1452-1458	HIF-1α	abstract	giv	_	_
12-10	1459-1460	)	_	_	_	_
12-11	1461-1462	,	_	_	_	_
12-12	1463-1470	causing	_	_	_	_
12-13	1471-1474	the	event[77]	new[77]	_	_
12-14	1475-1482	release	event[77]	new[77]	_	_
12-15	1483-1485	of	event[77]	new[77]	_	_
12-16	1486-1494	vascular	event[77]|abstract[80]	new[77]|new[80]	coref	14-10[93_80]
12-17	1495-1506	endothelial	event[77]|abstract|abstract[80]	new[77]|new|new[80]	_	_
12-18	1507-1513	growth	event[77]|abstract|abstract[80]	new[77]|new|new[80]	coref	13-12[90_0]
12-19	1514-1520	factor	event[77]|abstract[80]	new[77]|new[80]	_	_
12-20	1521-1522	(	_	_	_	_
12-21	1523-1527	VEGF	object	new	coref	13-4
12-22	1528-1529	)	_	_	_	_
12-23	1530-1532	by	_	_	_	_
12-24	1533-1539	glioma	abstract|object[83]	new|new[83]	coref|coref	21-9[134_0]|21-9[134_0]
12-25	1540-1545	cells	object[83]	new[83]	_	_
12-26	1546-1554	affected	_	_	_	_
12-27	1555-1557	by	_	_	_	_
12-28	1558-1565	hypoxia	event	giv	coref	14-6
12-29	1566-1567	.	_	_	_	_

#Text=The task of VEGF is to counteract oxygen deficiency by inducing vascular network growth .
13-1	1568-1571	The	abstract[85]	new[85]	_	_
13-2	1572-1576	task	abstract[85]	new[85]	_	_
13-3	1577-1579	of	abstract[85]	new[85]	_	_
13-4	1580-1584	VEGF	abstract[85]|substance	new[85]|giv	coref	16-3
13-5	1585-1587	is	_	_	_	_
13-6	1588-1590	to	_	_	_	_
13-7	1591-1601	counteract	_	_	_	_
13-8	1602-1608	oxygen	substance|abstract[88]	new|new[88]	_	_
13-9	1609-1619	deficiency	abstract[88]	new[88]	_	_
13-10	1620-1622	by	_	_	_	_
13-11	1623-1631	inducing	_	_	_	_
13-12	1632-1640	vascular	abstract[90]	giv[90]	coref	30-3[177_90]
13-13	1641-1648	network	abstract|abstract[90]	giv|giv[90]	_	_
13-14	1649-1655	growth	abstract[90]	giv[90]	_	_
13-15	1656-1657	.	_	_	_	_

#Text=In spite of this , hypoxia may not be the only trigger factor for angiogenesis .
14-1	1658-1660	In	_	_	_	_
14-2	1661-1666	spite	_	_	_	_
14-3	1667-1669	of	_	_	_	_
14-4	1670-1674	this	_	_	_	_
14-5	1675-1676	,	_	_	_	_
14-6	1677-1684	hypoxia	substance	giv	coref	15-12[99_0]
14-7	1685-1688	may	_	_	_	_
14-8	1689-1692	not	_	_	_	_
14-9	1693-1695	be	_	_	_	_
14-10	1696-1699	the	abstract[93]	giv[93]	_	_
14-11	1700-1704	only	abstract[93]	giv[93]	_	_
14-12	1705-1712	trigger	person|abstract[93]	new|giv[93]	_	_
14-13	1713-1719	factor	abstract[93]	giv[93]	_	_
14-14	1720-1723	for	abstract[93]	giv[93]	_	_
14-15	1724-1736	angiogenesis	abstract[93]|abstract	giv[93]|giv	ana	15-1
14-16	1737-1738	.	_	_	_	_

#Text=This applies particularly to the initial stages of carcinogenesis , when cell hypoxia is not yet severe .
15-1	1739-1743	This	abstract	giv	coref	18-15
15-2	1744-1751	applies	_	_	_	_
15-3	1752-1764	particularly	_	_	_	_
15-4	1765-1767	to	_	_	_	_
15-5	1768-1771	the	abstract[96]	new[96]	_	_
15-6	1772-1779	initial	abstract[96]	new[96]	_	_
15-7	1780-1786	stages	abstract[96]	new[96]	_	_
15-8	1787-1789	of	abstract[96]	new[96]	_	_
15-9	1790-1804	carcinogenesis	abstract[96]|abstract	new[96]|new	_	_
15-10	1805-1806	,	_	_	_	_
15-11	1807-1811	when	_	_	_	_
15-12	1812-1816	cell	place|event[99]	giv|giv[99]	coref|coref|coref|coref	16-13[0_99]|19-25|16-13[0_99]|19-25
15-13	1817-1824	hypoxia	event[99]	giv[99]	_	_
15-14	1825-1827	is	_	_	_	_
15-15	1828-1831	not	_	_	_	_
15-16	1832-1835	yet	_	_	_	_
15-17	1836-1842	severe	_	_	_	_
15-18	1843-1844	.	_	_	_	_

#Text=Regulation of VEGF secretion also takes place by a mechanism independent of hypoxia , involving dysregulated activation of mitogenic and survival pathways .
16-1	1845-1855	Regulation	event[100]	new[100]	_	_
16-2	1856-1858	of	event[100]	new[100]	_	_
16-3	1859-1863	VEGF	event[100]|abstract|abstract[102]	new[100]|giv|new[102]	coref|coref	18-13|18-13
16-4	1864-1873	secretion	event[100]|abstract[102]	new[100]|new[102]	_	_
16-5	1874-1878	also	_	_	_	_
16-6	1879-1884	takes	_	_	_	_
16-7	1885-1890	place	_	_	_	_
16-8	1891-1893	by	_	_	_	_
16-9	1894-1895	a	abstract[103]	giv[103]	_	_
16-10	1896-1905	mechanism	abstract[103]	giv[103]	_	_
16-11	1906-1917	independent	abstract[103]	giv[103]	_	_
16-12	1918-1920	of	_	_	_	_
16-13	1921-1928	hypoxia	event	giv	_	_
16-14	1929-1930	,	_	_	_	_
16-15	1931-1940	involving	_	_	_	_
16-16	1941-1953	dysregulated	abstract[105]	new[105]	ana	17-1[0_105]
16-17	1954-1964	activation	abstract[105]	new[105]	_	_
16-18	1965-1967	of	abstract[105]	new[105]	_	_
16-19	1968-1977	mitogenic	abstract[105]|place	new[105]|new	_	_
16-20	1978-1981	and	abstract[105]	new[105]	_	_
16-21	1982-1990	survival	abstract[105]|event|place[108]	new[105]|new|new[108]	coref|coref	28-13[0_108]|28-13[0_108]
16-22	1991-1999	pathways	abstract[105]|place[108]	new[105]|new[108]	_	_
16-23	2000-2001	.	_	_	_	_

#Text=This applies to phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase .
17-1	2002-2006	This	abstract	giv	_	_
17-2	2007-2014	applies	_	_	_	_
17-3	2015-2017	to	_	_	_	_
17-4	2018-2038	phosphatidylinositol	person	new	_	_
17-5	2039-2047	3-kinase	_	_	_	_
17-6	2048-2051	and	_	_	_	_
17-7	2052-2073	Ras/mitogen-activated	abstract[112]	new[112]	_	_
17-8	2074-2081	protein	substance|abstract[112]	new|new[112]	_	_
17-9	2082-2088	kinase	abstract[112]	new[112]	_	_
17-10	2089-2090	.	_	_	_	_

#Text=The PD-L1/PD-1 axis may also have roles in regulating the level of VEGF mediating angiogenesis .
18-1	2091-2094	The	abstract[114]	new[114]	coref	24-20[150_114]
18-2	2095-2105	PD-L1/PD-1	object|abstract[114]	new|new[114]	_	_
18-3	2106-2110	axis	abstract[114]	new[114]	_	_
18-4	2111-2114	may	_	_	_	_
18-5	2115-2119	also	_	_	_	_
18-6	2120-2124	have	_	_	_	_
18-7	2125-2130	roles	abstract	new	_	_
18-8	2131-2133	in	_	_	_	_
18-9	2134-2144	regulating	_	_	_	_
18-10	2145-2148	the	abstract[116]	new[116]	_	_
18-11	2149-2154	level	abstract[116]	new[116]	_	_
18-12	2155-2157	of	abstract[116]	new[116]	_	_
18-13	2158-2162	VEGF	abstract[116]|abstract	new[116]|giv	coref	19-16
18-14	2163-2172	mediating	_	_	_	_
18-15	2173-2185	angiogenesis	abstract	giv	coref	27-3[160_0]
18-16	2186-2187	.	_	_	_	_

#Text=In studies conducted by Shin et al. , a positive correlation between PDL1 levels and VEGF expression was shown in 197 patients with renal cell carcinoma .
19-1	2188-2190	In	_	_	_	_
19-2	2191-2198	studies	event	new	coref	23-1[141_0]
19-3	2199-2208	conducted	_	_	_	_
19-4	2209-2211	by	_	_	_	_
19-5	2212-2216	Shin	person	new	_	_
19-6	2217-2219	et	_	_	_	_
19-7	2220-2223	al.	_	_	_	_
19-8	2224-2225	,	_	_	_	_
19-9	2226-2227	a	abstract[121]	new[121]	_	_
19-10	2228-2236	positive	abstract[121]	new[121]	_	_
19-11	2237-2248	correlation	abstract[121]	new[121]	_	_
19-12	2249-2256	between	abstract[121]	new[121]	_	_
19-13	2257-2261	PDL1	abstract[121]|abstract|abstract[123]	new[121]|new|new[123]	coref|coref	22-6[138_123]|22-6[138_123]
19-14	2262-2268	levels	abstract[121]|abstract[123]	new[121]|new[123]	_	_
19-15	2269-2272	and	abstract[121]	new[121]	_	_
19-16	2273-2277	VEGF	abstract[121]|abstract|abstract[125]	new[121]|giv|new[125]	coref|coref|coref|coref	22-7[0_125]|22-12|22-7[0_125]|22-12
19-17	2278-2288	expression	abstract[121]|abstract[125]	new[121]|new[125]	_	_
19-18	2289-2292	was	_	_	_	_
19-19	2293-2298	shown	_	_	_	_
19-20	2299-2301	in	_	_	_	_
19-21	2302-2305	197	person[126]	new[126]	_	_
19-22	2306-2314	patients	person[126]	new[126]	_	_
19-23	2315-2319	with	person[126]	new[126]	_	_
19-24	2320-2325	renal	person[126]|abstract|object[129]	new[126]|new|new[129]	_	_
19-25	2326-2330	cell	person[126]|place|object[129]	new[126]|giv|new[129]	coref	27-11
19-26	2331-2340	carcinoma	person[126]|object[129]	new[126]|new[129]	_	_
19-27	2341-2342	.	_	_	_	_

#Text=Similar observations were noted by Song et al.
20-1	2343-2350	Similar	abstract[130]	new[130]	_	_
20-2	2351-2363	observations	abstract[130]	new[130]	_	_
20-3	2364-2368	were	_	_	_	_
20-4	2369-2374	noted	_	_	_	_
20-5	2375-2377	by	_	_	_	_
20-6	2378-2382	Song	person	new	_	_
20-7	2383-2385	et	_	_	_	_
20-8	2386-2389	al.	_	_	_	_

#Text=The study was conducted in 64 patients with primary glioma .
21-1	2390-2393	The	event[132]	new[132]	_	_
21-2	2394-2399	study	event[132]	new[132]	_	_
21-3	2400-2403	was	_	_	_	_
21-4	2404-2413	conducted	_	_	_	_
21-5	2414-2416	in	_	_	_	_
21-6	2417-2419	64	person[133]	new[133]	ana	22-3[0_133]
21-7	2420-2428	patients	person[133]	new[133]	_	_
21-8	2429-2433	with	person[133]	new[133]	_	_
21-9	2434-2441	primary	person[133]|abstract[134]	new[133]|giv[134]	_	_
21-10	2442-2448	glioma	person[133]|abstract[134]	new[133]|giv[134]	_	_
21-11	2449-2450	.	_	_	_	_

#Text=Also , they showed that PD-L1 expression levels correlated well with VEGF levels .
22-1	2451-2455	Also	_	_	_	_
22-2	2456-2457	,	_	_	_	_
22-3	2458-2462	they	person	giv	_	_
22-4	2463-2469	showed	_	_	_	_
22-5	2470-2474	that	_	_	_	_
22-6	2475-2480	PD-L1	abstract|abstract[138]	new|giv[138]	coref|coref	22-12[140_138]|22-12[140_138]
22-7	2481-2491	expression	abstract|abstract[138]	giv|giv[138]	coref	40-1[245_0]
22-8	2492-2498	levels	abstract[138]	giv[138]	_	_
22-9	2499-2509	correlated	_	_	_	_
22-10	2510-2514	well	_	_	_	_
22-11	2515-2519	with	_	_	_	_
22-12	2520-2524	VEGF	abstract|abstract[140]	giv|giv[140]	_	_
22-13	2525-2531	levels	abstract[140]	giv[140]	_	_
22-14	2532-2533	.	_	_	_	_

#Text=However , not all studies agreed on this point .
23-1	2534-2541	However	event[141]	giv[141]	_	_
23-2	2542-2543	,	event[141]	giv[141]	_	_
23-3	2544-2547	not	event[141]	giv[141]	_	_
23-4	2548-2551	all	event[141]	giv[141]	_	_
23-5	2552-2559	studies	event[141]	giv[141]	_	_
23-6	2560-2566	agreed	_	_	_	_
23-7	2567-2569	on	_	_	_	_
23-8	2570-2574	this	abstract[142]	new[142]	_	_
23-9	2575-2580	point	abstract[142]	new[142]	_	_
23-10	2581-2582	.	_	_	_	_

#Text=Research by Joseph et al. indicates the existence of a negative relationship between VEGF-related genes and the activity of the PD-L1/PD1 axis .
24-1	2583-2591	Research	organization[143]	new[143]	_	_
24-2	2592-2594	by	organization[143]	new[143]	_	_
24-3	2595-2601	Joseph	organization[143]|person	new[143]|new	_	_
24-4	2602-2604	et	organization[143]	new[143]	_	_
24-5	2605-2608	al.	organization[143]	new[143]	_	_
24-6	2609-2618	indicates	_	_	_	_
24-7	2619-2622	the	abstract[145]	new[145]	_	_
24-8	2623-2632	existence	abstract[145]	new[145]	_	_
24-9	2633-2635	of	abstract[145]	new[145]	_	_
24-10	2636-2637	a	abstract[145]|abstract[146]	new[145]|new[146]	coref	25-8[153_146]
24-11	2638-2646	negative	abstract[145]|abstract[146]	new[145]|new[146]	_	_
24-12	2647-2659	relationship	abstract[145]|abstract[146]	new[145]|new[146]	_	_
24-13	2660-2667	between	abstract[145]|abstract[146]	new[145]|new[146]	_	_
24-14	2668-2680	VEGF-related	abstract[145]|abstract[146]|abstract[147]	new[145]|new[146]|new[147]	_	_
24-15	2681-2686	genes	abstract[145]|abstract[146]|abstract[147]	new[145]|new[146]|new[147]	_	_
24-16	2687-2690	and	abstract[145]|abstract[146]	new[145]|new[146]	_	_
24-17	2691-2694	the	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
24-18	2695-2703	activity	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
24-19	2704-2706	of	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
24-20	2707-2710	the	abstract[145]|abstract[146]|abstract[148]|abstract[150]	new[145]|new[146]|new[148]|giv[150]	_	_
24-21	2711-2720	PD-L1/PD1	abstract[145]|abstract[146]|abstract[148]|object|abstract[150]	new[145]|new[146]|new[148]|new|giv[150]	_	_
24-22	2721-2725	axis	abstract[145]|abstract[146]|abstract[148]|abstract[150]	new[145]|new[146]|new[148]|giv[150]	_	_
24-23	2726-2727	.	_	_	_	_

#Text=A thorough understanding of the nature of this relationship requires further work .
25-1	2728-2729	A	abstract[151]	new[151]	_	_
25-2	2730-2738	thorough	abstract[151]	new[151]	_	_
25-3	2739-2752	understanding	abstract[151]	new[151]	_	_
25-4	2753-2755	of	abstract[151]	new[151]	_	_
25-5	2756-2759	the	abstract[151]|abstract[152]	new[151]|new[152]	_	_
25-6	2760-2766	nature	abstract[151]|abstract[152]	new[151]|new[152]	_	_
25-7	2767-2769	of	abstract[151]|abstract[152]	new[151]|new[152]	_	_
25-8	2770-2774	this	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|giv[153]	_	_
25-9	2775-2787	relationship	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|giv[153]	_	_
25-10	2788-2796	requires	_	_	_	_
25-11	2797-2804	further	abstract[154]	new[154]	ana	27-1[0_154]
25-12	2805-2809	work	abstract[154]	new[154]	_	_
25-13	2810-2811	.	_	_	_	_

#Text=EGF is another molecule with similar effects .
26-1	2812-2815	EGF	substance	new	coref	26-3[156_0]
26-2	2816-2818	is	_	_	_	_
26-3	2819-2826	another	substance[156]	giv[156]	coref	39-7[239_156]
26-4	2827-2835	molecule	substance[156]	giv[156]	_	_
26-5	2836-2840	with	substance[156]	giv[156]	_	_
26-6	2841-2848	similar	substance[156]|abstract[157]	giv[156]|new[157]	_	_
26-7	2849-2856	effects	substance[156]|abstract[157]	giv[156]|new[157]	_	_
26-8	2857-2858	.	_	_	_	_

#Text=It promotes tumor angiogenesis as well as an increase in cell motility and invasiveness .
27-1	2859-2861	It	abstract	giv	_	_
27-2	2862-2870	promotes	_	_	_	_
27-3	2871-2876	tumor	abstract|abstract[160]	new|giv[160]	coref|coref|coref|coref	29-15[175_160]|30-6|29-15[175_160]|30-6
27-4	2877-2889	angiogenesis	abstract[160]	giv[160]	_	_
27-5	2890-2892	as	_	_	_	_
27-6	2893-2897	well	_	_	_	_
27-7	2898-2900	as	_	_	_	_
27-8	2901-2903	an	abstract[161]	new[161]	ana	28-1[0_161]
27-9	2904-2912	increase	abstract[161]	new[161]	_	_
27-10	2913-2915	in	abstract[161]	new[161]	_	_
27-11	2916-2920	cell	abstract[161]|place|abstract[163]	new[161]|giv|new[163]	coref|coref	32-14|32-14
27-12	2921-2929	motility	abstract[161]|abstract[163]	new[161]|new[163]	_	_
27-13	2930-2933	and	abstract[161]	new[161]	_	_
27-14	2934-2946	invasiveness	abstract[161]|abstract	new[161]|giv	coref	38-14[236_0]
27-15	2947-2948	.	_	_	_	_

#Text=This is done by phosphorylating the EGFR receptor and activating further signaling pathways .
28-1	2949-2953	This	abstract	giv	ana	29-1
28-2	2954-2956	is	_	_	_	_
28-3	2957-2961	done	_	_	_	_
28-4	2962-2964	by	_	_	_	_
28-5	2965-2980	phosphorylating	_	_	_	_
28-6	2981-2984	the	substance[167]	new[167]	coref	37-25[228_167]
28-7	2985-2989	EGFR	abstract|substance[167]	new|new[167]	coref	29-6[170_0]
28-8	2990-2998	receptor	substance[167]	new[167]	_	_
28-9	2999-3002	and	_	_	_	_
28-10	3003-3013	activating	_	_	_	_
28-11	3014-3021	further	_	_	_	_
28-12	3022-3031	signaling	_	_	_	_
28-13	3032-3040	pathways	place	giv	_	_
28-14	3041-3042	.	_	_	_	_

#Text=It has been shown that both EGFR and its mutated form of EGFRvIII promote GBM angiogenesis .
29-1	3043-3045	It	abstract	giv	ana	29-9
29-2	3046-3049	has	_	_	_	_
29-3	3050-3054	been	_	_	_	_
29-4	3055-3060	shown	_	_	_	_
29-5	3061-3065	that	_	_	_	_
29-6	3066-3070	both	abstract[170]	giv[170]	coref	31-9[0_170]
29-7	3071-3075	EGFR	abstract[170]	giv[170]	_	_
29-8	3076-3079	and	_	_	_	_
29-9	3080-3083	its	abstract|abstract[172]	giv|new[172]	coref|coref	31-11[188_0]|31-11[188_0]
29-10	3084-3091	mutated	abstract[172]	new[172]	_	_
29-11	3092-3096	form	abstract[172]	new[172]	_	_
29-12	3097-3099	of	abstract[172]	new[172]	_	_
29-13	3100-3108	EGFRvIII	abstract[172]|abstract	new[172]|new	_	_
29-14	3109-3116	promote	_	_	_	_
29-15	3117-3120	GBM	abstract|abstract[175]	giv|giv[175]	coref|coref	32-26[0_175]|32-26[0_175]
29-16	3121-3133	angiogenesis	abstract[175]	giv[175]	_	_
29-17	3134-3135	.	_	_	_	_

#Text=To allow vasculature growth and tumor invasion , it is necessary to reduce the integrity of the tumor microenvironment .
30-1	3136-3138	To	_	_	_	_
30-2	3139-3144	allow	_	_	_	_
30-3	3145-3156	vasculature	organization|abstract[177]	new|giv[177]	coref|coref	42-17[0_177]|42-17[0_177]
30-4	3157-3163	growth	abstract[177]	giv[177]	_	_
30-5	3164-3167	and	_	_	_	_
30-6	3168-3173	tumor	abstract|event[179]	giv|new[179]	coref|coref|coref|coref	30-18|32-13[202_179]|30-18|32-13[202_179]
30-7	3174-3182	invasion	event[179]	new[179]	_	_
30-8	3183-3184	,	_	_	_	_
30-9	3185-3187	it	abstract	new	cata	30-9[0_181]
30-10	3188-3190	is	_	_	_	_
30-11	3191-3200	necessary	_	_	_	_
30-12	3201-3203	to	abstract[181]	new[181]	_	_
30-13	3204-3210	reduce	abstract[181]	new[181]	_	_
30-14	3211-3214	the	abstract[181]|abstract[182]	new[181]|new[182]	coref	32-7[199_182]
30-15	3215-3224	integrity	abstract[181]|abstract[182]	new[181]|new[182]	_	_
30-16	3225-3227	of	abstract[181]|abstract[182]	new[181]|new[182]	_	_
30-17	3228-3231	the	abstract[181]|abstract[182]|abstract[184]	new[181]|new[182]|new[184]	coref	32-7[0_184]
30-18	3232-3237	tumor	abstract[181]|abstract[182]|abstract|abstract[184]	new[181]|new[182]|giv|new[184]	coref	41-10
30-19	3238-3254	microenvironment	abstract[181]|abstract[182]|abstract[184]	new[181]|new[182]|new[184]	_	_
30-20	3255-3256	.	_	_	_	_

#Text=The pathophysiology of this process is based on EGFR inducing an increase in the activity of some proteases , thereby causing the breakdown of collagen , fibronectin , and other basement membrane structures .
31-1	3257-3260	The	abstract[185]	new[185]	_	_
31-2	3261-3276	pathophysiology	abstract[185]	new[185]	_	_
31-3	3277-3279	of	abstract[185]	new[185]	_	_
31-4	3280-3284	this	abstract[185]|event[186]	new[185]|new[186]	_	_
31-5	3285-3292	process	abstract[185]|event[186]	new[185]|new[186]	_	_
31-6	3293-3295	is	_	_	_	_
31-7	3296-3301	based	_	_	_	_
31-8	3302-3304	on	_	_	_	_
31-9	3305-3309	EGFR	abstract	giv	coref	33-8
31-10	3310-3318	inducing	_	_	_	_
31-11	3319-3321	an	abstract[188]	giv[188]	coref	32-23[205_188]
31-12	3322-3330	increase	abstract[188]	giv[188]	_	_
31-13	3331-3333	in	abstract[188]	giv[188]	_	_
31-14	3334-3337	the	abstract[188]|abstract[189]	giv[188]|new[189]	coref	33-3[208_189]
31-15	3338-3346	activity	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
31-16	3347-3349	of	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
31-17	3350-3354	some	abstract[188]|abstract[189]|object[190]	giv[188]|new[189]|new[190]	coref	33-1[207_190]
31-18	3355-3364	proteases	abstract[188]|abstract[189]|object[190]	giv[188]|new[189]|new[190]	_	_
31-19	3365-3366	,	_	_	_	_
31-20	3367-3374	thereby	_	_	_	_
31-21	3375-3382	causing	_	_	_	_
31-22	3383-3386	the	event[191]	new[191]	_	_
31-23	3387-3396	breakdown	event[191]	new[191]	_	_
31-24	3397-3399	of	event[191]	new[191]	_	_
31-25	3400-3408	collagen	event[191]|object	new[191]|new	_	_
31-26	3409-3410	,	event[191]	new[191]	_	_
31-27	3411-3422	fibronectin	event[191]|object	new[191]|new	_	_
31-28	3423-3424	,	event[191]	new[191]	_	_
31-29	3425-3428	and	event[191]	new[191]	_	_
31-30	3429-3434	other	event[191]|object[195]	new[191]|new[195]	_	_
31-31	3435-3443	basement	event[191]|object[195]	new[191]|new[195]	_	_
31-32	3444-3452	membrane	event[191]|object|object[195]	new[191]|new|new[195]	_	_
31-33	3453-3463	structures	event[191]|object[195]	new[191]|new[195]	_	_
31-34	3464-3465	.	_	_	_	_

#Text=The result is a loss of microenvironment integrity , an increase in tumor cell invasion into surrounding tissues and vessels , and an increase in angiogenesis .
32-1	3466-3469	The	abstract[196]	new[196]	coref	32-4[197_196]
32-2	3470-3476	result	abstract[196]	new[196]	_	_
32-3	3477-3479	is	_	_	_	_
32-4	3480-3481	a	abstract[197]	giv[197]	_	_
32-5	3482-3486	loss	abstract[197]	giv[197]	_	_
32-6	3487-3489	of	abstract[197]	giv[197]	_	_
32-7	3490-3506	microenvironment	abstract[197]|abstract|abstract[199]	giv[197]|giv|giv[199]	appos|coref|appos|coref	32-10[200_199]|50-15[321_0]|32-10[200_199]|50-15[321_0]
32-8	3507-3516	integrity	abstract[197]|abstract[199]	giv[197]|giv[199]	_	_
32-9	3517-3518	,	_	_	_	_
32-10	3519-3521	an	abstract[200]	giv[200]	coref	46-10[290_200]
32-11	3522-3530	increase	abstract[200]	giv[200]	_	_
32-12	3531-3533	in	abstract[200]	giv[200]	_	_
32-13	3534-3539	tumor	abstract[200]|event[202]	giv[200]|giv[202]	coref	48-7[307_202]
32-14	3540-3544	cell	abstract[200]|place|event[202]	giv[200]|giv|giv[202]	coref	45-18
32-15	3545-3553	invasion	abstract[200]|event[202]	giv[200]|giv[202]	_	_
32-16	3554-3558	into	abstract[200]|event[202]	giv[200]|giv[202]	_	_
32-17	3559-3570	surrounding	abstract[200]|event[202]|object[203]	giv[200]|giv[202]|new[203]	_	_
32-18	3571-3578	tissues	abstract[200]|event[202]|object[203]	giv[200]|giv[202]|new[203]	_	_
32-19	3579-3582	and	abstract[200]|event[202]	giv[200]|giv[202]	_	_
32-20	3583-3590	vessels	abstract[200]|event[202]|object	giv[200]|giv[202]|new	_	_
32-21	3591-3592	,	abstract[200]|event[202]	giv[200]|giv[202]	_	_
32-22	3593-3596	and	abstract[200]|event[202]	giv[200]|giv[202]	_	_
32-23	3597-3599	an	abstract[200]|event[202]|abstract[205]	giv[200]|giv[202]|giv[205]	coref	40-6[246_205]
32-24	3600-3608	increase	abstract[200]|event[202]|abstract[205]	giv[200]|giv[202]|giv[205]	_	_
32-25	3609-3611	in	abstract[200]|event[202]|abstract[205]	giv[200]|giv[202]|giv[205]	_	_
32-26	3612-3624	angiogenesis	abstract[200]|event[202]|abstract[205]|abstract	giv[200]|giv[202]|giv[205]|giv	_	_
32-27	3625-3626	.	_	_	_	_

#Text=The proteases whose activity is influenced by EGFR include , among others :
33-1	3627-3630	The	object[207]	giv[207]	coref	37-1[218_207]
33-2	3631-3640	proteases	object[207]	giv[207]	_	_
33-3	3641-3646	whose	abstract[208]	giv[208]	coref	41-4[250_208]
33-4	3647-3655	activity	abstract[208]	giv[208]	_	_
33-5	3656-3658	is	_	_	_	_
33-6	3659-3669	influenced	_	_	_	_
33-7	3670-3672	by	_	_	_	_
33-8	3673-3677	EGFR	abstract	giv	coref	42-14
33-9	3678-3685	include	_	_	_	_
33-10	3686-3687	,	_	_	_	_
33-11	3688-3693	among	_	_	_	_
33-12	3694-3700	others	_	_	_	_
33-13	3701-3702	:	_	_	_	_

#Text=Serine Proteases
34-1	3703-3709	Serine	substance[210]	new[210]	coref	37-1[0_210]
34-2	3710-3719	Proteases	substance[210]|abstract	new[210]|new	coref	36-1[216_0]

#Text=Matrix Metalloproteases ( MMPs )
35-1	3720-3726	Matrix	abstract|object[213]	new|new[213]	appos|coref|appos|coref	35-4[0_213]|47-10|35-4[0_213]|47-10
35-2	3727-3743	Metalloproteases	object[213]	new[213]	_	_
35-3	3744-3745	(	_	_	_	_
35-4	3746-3750	MMPs	object	giv	coref	44-16
35-5	3751-3752	)	_	_	_	_

#Text=Cysteine Proteases .
36-1	3753-3761	Cysteine	abstract|abstract[216]	new|giv[216]	coref|coref	49-6|49-6
36-2	3762-3771	Proteases	abstract[216]	giv[216]	_	_
36-3	3772-3773	.	_	_	_	_

#Text=Serine proteases are a large group of proteases which include tissue plasminogen activator ( tPA ) and urokinase plasminogen activator ( uPA ) with its receptor ( uPAR ) .
37-1	3774-3780	Serine	substance|abstract[218]	giv|giv[218]	coref|coref	37-4[219_218]|37-4[219_218]
37-2	3781-3790	proteases	abstract[218]	giv[218]	_	_
37-3	3791-3794	are	_	_	_	_
37-4	3795-3796	a	abstract[219]	giv[219]	ana	38-1[0_219]
37-5	3797-3802	large	abstract[219]	giv[219]	_	_
37-6	3803-3808	group	abstract[219]	giv[219]	_	_
37-7	3809-3811	of	abstract[219]	giv[219]	_	_
37-8	3812-3821	proteases	abstract[219]	giv[219]	_	_
37-9	3822-3827	which	_	_	_	_
37-10	3828-3835	include	_	_	_	_
37-11	3836-3842	tissue	object|organization[222]	new|new[222]	appos|appos	37-15[0_222]|37-15[0_222]
37-12	3843-3854	plasminogen	substance|organization[222]	new|new[222]	coref	37-19
37-13	3855-3864	activator	organization[222]	new[222]	_	_
37-14	3865-3866	(	_	_	_	_
37-15	3867-3870	tPA	organization	giv	_	_
37-16	3871-3872	)	_	_	_	_
37-17	3873-3876	and	_	_	_	_
37-18	3877-3886	urokinase	organization[225]	new[225]	appos	37-22[0_225]
37-19	3887-3898	plasminogen	substance|organization[225]	giv|new[225]	_	_
37-20	3899-3908	activator	organization[225]	new[225]	_	_
37-21	3909-3910	(	_	_	_	_
37-22	3911-3914	uPA	organization	giv	ana	37-25
37-23	3915-3916	)	_	_	_	_
37-24	3917-3921	with	_	_	_	_
37-25	3922-3925	its	organization|substance[228]	giv|giv[228]	coref|coref	42-3|42-3
37-26	3926-3934	receptor	substance[228]	giv[228]	_	_
37-27	3935-3936	(	_	_	_	_
37-28	3937-3941	uPAR	organization	new	coref	42-5
37-29	3942-3943	)	_	_	_	_
37-30	3944-3945	.	_	_	_	_

#Text=Their activation affects the degradation of the extracellular space by tumors , promoting their invasiveness .
38-1	3946-3951	Their	object|abstract[231]	giv|new[231]	ana|ana	38-14|38-14
38-2	3952-3962	activation	abstract[231]	new[231]	_	_
38-3	3963-3970	affects	_	_	_	_
38-4	3971-3974	the	abstract[232]	new[232]	ana	39-1[0_232]
38-5	3975-3986	degradation	abstract[232]	new[232]	_	_
38-6	3987-3989	of	abstract[232]	new[232]	_	_
38-7	3990-3993	the	abstract[232]|place[233]	new[232]|new[233]	_	_
38-8	3994-4007	extracellular	abstract[232]|place[233]	new[232]|new[233]	_	_
38-9	4008-4013	space	abstract[232]|place[233]	new[232]|new[233]	_	_
38-10	4014-4016	by	abstract[232]|place[233]	new[232]|new[233]	_	_
38-11	4017-4023	tumors	abstract[232]|place[233]|object	new[232]|new[233]|new	_	_
38-12	4024-4025	,	_	_	_	_
38-13	4026-4035	promoting	_	_	_	_
38-14	4036-4041	their	abstract|abstract[236]	giv|giv[236]	coref|coref|coref|coref	41-10[252_236]|44-11[274_0]|41-10[252_236]|44-11[274_0]
38-15	4042-4054	invasiveness	abstract[236]	giv[236]	_	_
38-16	4055-4056	.	_	_	_	_

#Text=It has been shown that , the PAI-1 molecule mediates the regulation of the uPA/uPAR pathway in astrocytoma cells .
39-1	4057-4059	It	abstract	giv	_	_
39-2	4060-4063	has	_	_	_	_
39-3	4064-4068	been	_	_	_	_
39-4	4069-4074	shown	_	_	_	_
39-5	4075-4079	that	_	_	_	_
39-6	4080-4081	,	_	_	_	_
39-7	4082-4085	the	substance[239]	giv[239]	ana	40-1[0_239]
39-8	4086-4091	PAI-1	substance|substance[239]	new|giv[239]	coref	43-8[264_0]
39-9	4092-4100	molecule	substance[239]	giv[239]	_	_
39-10	4101-4109	mediates	_	_	_	_
39-11	4110-4113	the	abstract[240]	new[240]	_	_
39-12	4114-4124	regulation	abstract[240]	new[240]	_	_
39-13	4125-4127	of	abstract[240]	new[240]	_	_
39-14	4128-4131	the	abstract[240]|place[242]	new[240]|new[242]	_	_
39-15	4132-4140	uPA/uPAR	abstract[240]|organization|place[242]	new[240]|new|new[242]	coref	41-5
39-16	4141-4148	pathway	abstract[240]|place[242]	new[240]|new[242]	_	_
39-17	4149-4151	in	abstract[240]|place[242]	new[240]|new[242]	_	_
39-18	4152-4163	astrocytoma	abstract[240]|place[242]|object[243]	new[240]|new[242]|new[243]	_	_
39-19	4164-4169	cells	abstract[240]|place[242]|object[243]	new[240]|new[242]|new[243]	_	_
39-20	4170-4171	.	_	_	_	_

#Text=Its expression is promoted by an increase in EGF and inflammatory cytokines .
40-1	4172-4175	Its	substance|abstract[245]	giv|giv[245]	coref|coref|coref|coref	40-9|42-10[256_245]|40-9|42-10[256_245]
40-2	4176-4186	expression	abstract[245]	giv[245]	_	_
40-3	4187-4189	is	_	_	_	_
40-4	4190-4198	promoted	_	_	_	_
40-5	4199-4201	by	_	_	_	_
40-6	4202-4204	an	abstract[246]	giv[246]	_	_
40-7	4205-4213	increase	abstract[246]	giv[246]	_	_
40-8	4214-4216	in	abstract[246]	giv[246]	_	_
40-9	4217-4220	EGF	abstract[246]|abstract	giv[246]|giv	coref	44-1
40-10	4221-4224	and	_	_	_	_
40-11	4225-4237	inflammatory	abstract[248]	new[248]	_	_
40-12	4238-4247	cytokines	abstract[248]	new[248]	_	_
40-13	4248-4249	.	_	_	_	_

#Text=This results in greater uPA/uPAR activity , thus increasing tumor invasiveness .
41-1	4250-4254	This	_	_	_	_
41-2	4255-4262	results	_	_	_	_
41-3	4263-4265	in	_	_	_	_
41-4	4266-4273	greater	abstract[250]	giv[250]	coref	43-11[266_250]
41-5	4274-4282	uPA/uPAR	organization|abstract[250]	giv|giv[250]	_	_
41-6	4283-4291	activity	abstract[250]	giv[250]	_	_
41-7	4292-4293	,	_	_	_	_
41-8	4294-4298	thus	_	_	_	_
41-9	4299-4309	increasing	_	_	_	_
41-10	4310-4315	tumor	abstract|abstract[252]	giv|giv[252]	coref|coref	43-16|43-16
41-11	4316-4328	invasiveness	abstract[252]	giv[252]	_	_
41-12	4329-4330	.	_	_	_	_

#Text=Upregulation of uPA and uPAR is also achieved through the expression of the EGFR ligand transforming growth factor ( TGFα ) .
42-1	4331-4343	Upregulation	abstract[253]	new[253]	_	_
42-2	4344-4346	of	abstract[253]	new[253]	_	_
42-3	4347-4350	uPA	abstract[253]|substance	new[253]|giv	coref	54-21
42-4	4351-4354	and	abstract[253]	new[253]	_	_
42-5	4355-4359	uPAR	abstract[253]|abstract	new[253]|giv	_	_
42-6	4360-4362	is	_	_	_	_
42-7	4363-4367	also	_	_	_	_
42-8	4368-4376	achieved	_	_	_	_
42-9	4377-4384	through	_	_	_	_
42-10	4385-4388	the	abstract[256]	giv[256]	coref	51-1[323_256]
42-11	4389-4399	expression	abstract[256]	giv[256]	_	_
42-12	4400-4402	of	abstract[256]	giv[256]	_	_
42-13	4403-4406	the	abstract[256]|abstract[258]	giv[256]|new[258]	_	_
42-14	4407-4411	EGFR	abstract[256]|abstract|abstract[258]	giv[256]|giv|new[258]	coref	43-11
42-15	4412-4418	ligand	abstract[256]|abstract[258]	giv[256]|new[258]	_	_
42-16	4419-4431	transforming	_	_	_	_
42-17	4432-4438	growth	abstract|abstract[260]	giv|new[260]	appos|appos	42-20[0_260]|42-20[0_260]
42-18	4439-4445	factor	abstract[260]	new[260]	_	_
42-19	4446-4447	(	_	_	_	_
42-20	4448-4452	TGFα	abstract	giv	_	_
42-21	4453-4454	)	_	_	_	_
42-22	4455-4456	.	_	_	_	_

#Text=Studies confirmed that in malignant gliomas , both PAI-1 and EGFR activity correlate with higher tumor malignancy and worse prognosis for patients .
43-1	4457-4464	Studies	abstract	new	_	_
43-2	4465-4474	confirmed	_	_	_	_
43-3	4475-4479	that	_	_	_	_
43-4	4480-4482	in	_	_	_	_
43-5	4483-4492	malignant	object[263]	new[263]	coref	47-39[303_263]
43-6	4493-4500	gliomas	object[263]	new[263]	_	_
43-7	4501-4502	,	_	_	_	_
43-8	4503-4507	both	substance[264]	giv[264]	_	_
43-9	4508-4513	PAI-1	substance[264]	giv[264]	_	_
43-10	4514-4517	and	_	_	_	_
43-11	4518-4522	EGFR	place|abstract[266]	giv|giv[266]	coref|coref	51-13|51-13
43-12	4523-4531	activity	abstract[266]	giv[266]	_	_
43-13	4532-4541	correlate	_	_	_	_
43-14	4542-4546	with	_	_	_	_
43-15	4547-4553	higher	abstract[268]	new[268]	coref	48-13[0_268]
43-16	4554-4559	tumor	event|abstract[268]	giv|new[268]	coref	48-7
43-17	4560-4570	malignancy	abstract[268]	new[268]	_	_
43-18	4571-4574	and	_	_	_	_
43-19	4575-4580	worse	abstract[269]	new[269]	_	_
43-20	4581-4590	prognosis	abstract[269]	new[269]	_	_
43-21	4591-4594	for	abstract[269]	new[269]	_	_
43-22	4595-4603	patients	abstract[269]|person	new[269]|new	ana	45-1
43-23	4604-4605	.	_	_	_	_

#Text=EGF also has a potential impact on another group of proteases , i. e. , MMPs .
44-1	4606-4609	EGF	abstract	giv	_	_
44-2	4610-4614	also	_	_	_	_
44-3	4615-4618	has	_	_	_	_
44-4	4619-4620	a	abstract[272]	new[272]	_	_
44-5	4621-4630	potential	abstract[272]	new[272]	_	_
44-6	4631-4637	impact	abstract[272]	new[272]	_	_
44-7	4638-4640	on	abstract[272]	new[272]	_	_
44-8	4641-4648	another	abstract[272]|abstract[273]	new[272]|new[273]	_	_
44-9	4649-4654	group	abstract[272]|abstract[273]	new[272]|new[273]	_	_
44-10	4655-4657	of	abstract[272]|abstract[273]	new[272]|new[273]	_	_
44-11	4658-4667	proteases	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	coref	49-4[0_274]
44-12	4668-4669	,	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	_	_
44-13	4670-4672	i.	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	_	_
44-14	4673-4675	e.	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	_	_
44-15	4676-4677	,	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	_	_
44-16	4678-4682	MMPs	abstract[272]|abstract[273]|object[274]|object	new[272]|new[273]|giv[274]|giv	coref	54-23
44-17	4683-4684	.	_	_	_	_

#Text=They are a large group of enzymes whose effect is based on the regulation of metabolism and cell morphogenesis .
45-1	4685-4689	They	abstract	giv	coref	45-3[277_0]
45-2	4690-4693	are	_	_	_	_
45-3	4694-4695	a	abstract[277]	giv[277]	_	_
45-4	4696-4701	large	abstract[277]	giv[277]	_	_
45-5	4702-4707	group	abstract[277]	giv[277]	_	_
45-6	4708-4710	of	abstract[277]	giv[277]	_	_
45-7	4711-4718	enzymes	abstract[277]|substance	giv[277]|new	_	_
45-8	4719-4724	whose	abstract[279]	new[279]	_	_
45-9	4725-4731	effect	abstract[279]	new[279]	_	_
45-10	4732-4734	is	_	_	_	_
45-11	4735-4740	based	_	_	_	_
45-12	4741-4743	on	_	_	_	_
45-13	4744-4747	the	abstract[280]	new[280]	_	_
45-14	4748-4758	regulation	abstract[280]	new[280]	_	_
45-15	4759-4761	of	abstract[280]	new[280]	_	_
45-16	4762-4772	metabolism	abstract[280]|abstract|abstract[282]	new[280]|new|new[282]	ana|ana	46-3[0_282]|46-3[0_282]
45-17	4773-4776	and	abstract[280]|abstract[282]	new[280]|new[282]	_	_
45-18	4777-4781	cell	abstract[280]|abstract[282]|place|abstract[284]	new[280]|new[282]|giv|new[284]	coref|coref	46-10|46-10
45-19	4782-4795	morphogenesis	abstract[280]|abstract[282]|abstract[284]	new[280]|new[282]|new[284]	_	_
45-20	4796-4797	.	_	_	_	_

#Text=Disruption of their function also affects the loss of cell integrity .
46-1	4798-4808	Disruption	abstract[285]	new[285]	_	_
46-2	4809-4811	of	abstract[285]	new[285]	_	_
46-3	4812-4817	their	abstract[285]|abstract|abstract[287]	new[285]|giv|new[287]	_	_
46-4	4818-4826	function	abstract[285]|abstract[287]	new[285]|new[287]	_	_
46-5	4827-4831	also	_	_	_	_
46-6	4832-4839	affects	_	_	_	_
46-7	4840-4843	the	event[288]	new[288]	ana	47-1[0_288]
46-8	4844-4848	loss	event[288]	new[288]	_	_
46-9	4849-4851	of	event[288]	new[288]	_	_
46-10	4852-4856	cell	event[288]|place|abstract[290]	new[288]|giv|giv[290]	_	_
46-11	4857-4866	integrity	event[288]|abstract[290]	new[288]|giv[290]	_	_
46-12	4867-4868	.	_	_	_	_

#Text=It has been shown that the activity of certain matrix metalloproteases , such as MMP-2 ( gelatinase A ) , MMP-9 ( gelatinase B ) , MMP-14 ( matrix metalloproteinase 14 ) is related to the pathophysiology of high-grade gliomas .
47-1	4869-4871	It	event	giv	_	_
47-2	4872-4875	has	_	_	_	_
47-3	4876-4880	been	_	_	_	_
47-4	4881-4886	shown	_	_	_	_
47-5	4887-4891	that	_	_	_	_
47-6	4892-4895	the	abstract[292]	new[292]	_	_
47-7	4896-4904	activity	abstract[292]	new[292]	_	_
47-8	4905-4907	of	abstract[292]	new[292]	_	_
47-9	4908-4915	certain	abstract[292]|object[294]	new[292]|new[294]	_	_
47-10	4916-4922	matrix	abstract[292]|abstract|object[294]	new[292]|giv|new[294]	coref	47-29
47-11	4923-4939	metalloproteases	abstract[292]|object[294]	new[292]|new[294]	_	_
47-12	4940-4941	,	abstract[292]	new[292]	_	_
47-13	4942-4946	such	abstract[292]	new[292]	_	_
47-14	4947-4949	as	abstract[292]	new[292]	_	_
47-15	4950-4955	MMP-2	abstract[292]|abstract	new[292]|new	appos	47-17
47-16	4956-4957	(	_	_	_	_
47-17	4958-4968	gelatinase	abstract	giv	appos	47-23[298_0]
47-18	4969-4970	A	_	_	_	_
47-19	4971-4972	)	_	_	_	_
47-20	4973-4974	,	_	_	_	_
47-21	4975-4980	MMP-9	substance	new	_	_
47-22	4981-4982	(	_	_	_	_
47-23	4983-4993	gelatinase	abstract[298]	giv[298]	_	_
47-24	4994-4995	B	abstract[298]	giv[298]	_	_
47-25	4996-4997	)	_	_	_	_
47-26	4998-4999	,	_	_	_	_
47-27	5000-5006	MMP-14	object	new	appos	47-29[301_0]
47-28	5007-5008	(	_	_	_	_
47-29	5009-5015	matrix	abstract|object[301]	giv|giv[301]	_	_
47-30	5016-5033	metalloproteinase	object[301]	giv[301]	_	_
47-31	5034-5036	14	object[301]	giv[301]	_	_
47-32	5037-5038	)	_	_	_	_
47-33	5039-5041	is	_	_	_	_
47-34	5042-5049	related	_	_	_	_
47-35	5050-5052	to	_	_	_	_
47-36	5053-5056	the	abstract[302]	new[302]	ana	48-1[0_302]
47-37	5057-5072	pathophysiology	abstract[302]	new[302]	_	_
47-38	5073-5075	of	abstract[302]	new[302]	_	_
47-39	5076-5086	high-grade	abstract[302]|object[303]	new[302]|giv[303]	coref	52-11[0_303]
47-40	5087-5094	gliomas	abstract[302]|object[303]	new[302]|giv[303]	_	_
47-41	5095-5096	.	_	_	_	_

#Text=It correlates with the severity of tumor invasion and its degree of malignancy .
48-1	5097-5099	It	abstract	giv	ana	48-10
48-2	5100-5110	correlates	_	_	_	_
48-3	5111-5115	with	_	_	_	_
48-4	5116-5119	the	abstract[305]	new[305]	_	_
48-5	5120-5128	severity	abstract[305]	new[305]	_	_
48-6	5129-5131	of	abstract[305]	new[305]	_	_
48-7	5132-5137	tumor	abstract[305]|abstract|event[307]	new[305]|giv|giv[307]	coref|coref	50-16|50-16
48-8	5138-5146	invasion	abstract[305]|event[307]	new[305]|giv[307]	_	_
48-9	5147-5150	and	abstract[305]	new[305]	_	_
48-10	5151-5154	its	abstract[305]|abstract|abstract[309]	new[305]|giv|new[309]	_	_
48-11	5155-5161	degree	abstract[305]|abstract[309]	new[305]|new[309]	_	_
48-12	5162-5164	of	abstract[305]|abstract[309]	new[305]|new[309]	_	_
48-13	5165-5175	malignancy	abstract[305]|abstract[309]|abstract	new[305]|new[309]|giv	_	_
48-14	5176-5177	.	_	_	_	_

#Text=Another group of proteases are cysteine proteases , examples of which are cathepsins .
49-1	5178-5185	Another	abstract[311]	new[311]	coref	49-6[314_311]
49-2	5186-5191	group	abstract[311]	new[311]	_	_
49-3	5192-5194	of	abstract[311]	new[311]	_	_
49-4	5195-5204	proteases	abstract[311]|object	new[311]|giv	_	_
49-5	5205-5208	are	_	_	_	_
49-6	5209-5217	cysteine	abstract|abstract[314]	giv|giv[314]	_	_
49-7	5218-5227	proteases	abstract[314]	giv[314]	_	_
49-8	5228-5229	,	_	_	_	_
49-9	5230-5238	examples	object	new	coref	49-13
49-10	5239-5241	of	_	_	_	_
49-11	5242-5247	which	_	_	_	_
49-12	5248-5251	are	_	_	_	_
49-13	5252-5262	cathepsins	object	giv	_	_
49-14	5263-5264	.	_	_	_	_

#Text=These include , among others , cathepsin B , involved in the degradation of the tumor microenvironment .
50-1	5265-5270	These	_	_	_	_
50-2	5271-5278	include	_	_	_	_
50-3	5279-5280	,	_	_	_	_
50-4	5281-5286	among	_	_	_	_
50-5	5287-5293	others	_	_	_	_
50-6	5294-5295	,	_	_	_	_
50-7	5296-5305	cathepsin	person|substance[318]	new|new[318]	ana|coref|ana|coref	51-1[0_318]|53-4|51-1[0_318]|53-4
50-8	5306-5307	B	substance[318]	new[318]	_	_
50-9	5308-5309	,	_	_	_	_
50-10	5310-5318	involved	_	_	_	_
50-11	5319-5321	in	_	_	_	_
50-12	5322-5325	the	event[319]	new[319]	_	_
50-13	5326-5337	degradation	event[319]	new[319]	_	_
50-14	5338-5340	of	event[319]	new[319]	_	_
50-15	5341-5344	the	event[319]|object[321]	new[319]|giv[321]	_	_
50-16	5345-5350	tumor	event[319]|abstract|object[321]	new[319]|giv|giv[321]	coref	54-12[339_0]
50-17	5351-5367	microenvironment	event[319]|object[321]	new[319]|giv[321]	_	_
50-18	5368-5369	.	_	_	_	_

#Text=Its expression ( mRNA level ) has been shown to correlate with EGFR expression level .
51-1	5370-5373	Its	substance|abstract[323]	giv|giv[323]	appos|coref|appos|coref	51-4[325_323]|53-4[334_0]|51-4[325_323]|53-4[334_0]
51-2	5374-5384	expression	abstract[323]	giv[323]	_	_
51-3	5385-5386	(	_	_	_	_
51-4	5387-5391	mRNA	place|abstract[325]	new|giv[325]	coref|coref	51-13[327_325]|51-13[327_325]
51-5	5392-5397	level	abstract[325]	giv[325]	_	_
51-6	5398-5399	)	_	_	_	_
51-7	5400-5403	has	_	_	_	_
51-8	5404-5408	been	_	_	_	_
51-9	5409-5414	shown	_	_	_	_
51-10	5415-5417	to	_	_	_	_
51-11	5418-5427	correlate	_	_	_	_
51-12	5428-5432	with	_	_	_	_
51-13	5433-5437	EGFR	place|abstract[327]	giv|giv[327]	ana|ana	52-1[0_327]|52-1[0_327]
51-14	5438-5448	expression	abstract[327]	giv[327]	_	_
51-15	5449-5454	level	abstract[327]	giv[327]	_	_
51-16	5455-5456	.	_	_	_	_

#Text=It was also confirmed that its presence is increased in gliomas .
52-1	5457-5459	It	abstract	giv	ana	52-6
52-2	5460-5463	was	_	_	_	_
52-3	5464-5468	also	_	_	_	_
52-4	5469-5478	confirmed	_	_	_	_
52-5	5479-5483	that	_	_	_	_
52-6	5484-5487	its	abstract|abstract[330]	giv|new[330]	_	_
52-7	5488-5496	presence	abstract[330]	new[330]	_	_
52-8	5497-5499	is	_	_	_	_
52-9	5500-5509	increased	_	_	_	_
52-10	5510-5512	in	_	_	_	_
52-11	5513-5520	gliomas	object	giv	_	_
52-12	5521-5522	.	_	_	_	_

#Text=The action of cathepsin B may be bidirectional .
53-1	5523-5526	The	abstract[332]	new[332]	ana	54-1[0_332]
53-2	5527-5533	action	abstract[332]	new[332]	_	_
53-3	5534-5536	of	abstract[332]	new[332]	_	_
53-4	5537-5546	cathepsin	abstract[332]|person|object[334]	new[332]|giv|giv[334]	_	_
53-5	5547-5548	B	abstract[332]|object[334]	new[332]|giv[334]	_	_
53-6	5549-5552	may	_	_	_	_
53-7	5553-5555	be	_	_	_	_
53-8	5556-5569	bidirectional	_	_	_	_
53-9	5570-5571	.	_	_	_	_

#Text=It promotes the degradation of the integrity of the environment of the tumor directly or through intermediate mediators such as uPA , MMPs , or plasmin .
54-1	5572-5574	It	abstract	giv	_	_
54-2	5575-5583	promotes	_	_	_	_
54-3	5584-5587	the	abstract[336]	new[336]	_	_
54-4	5588-5599	degradation	abstract[336]	new[336]	_	_
54-5	5600-5602	of	abstract[336]	new[336]	_	_
54-6	5603-5606	the	abstract[336]|abstract[337]	new[336]|new[337]	_	_
54-7	5607-5616	integrity	abstract[336]|abstract[337]	new[336]|new[337]	_	_
54-8	5617-5619	of	abstract[336]|abstract[337]	new[336]|new[337]	_	_
54-9	5620-5623	the	abstract[336]|abstract[337]|place[338]	new[336]|new[337]|new[338]	_	_
54-10	5624-5635	environment	abstract[336]|abstract[337]|place[338]	new[336]|new[337]|new[338]	_	_
54-11	5636-5638	of	abstract[336]|abstract[337]|place[338]	new[336]|new[337]|new[338]	_	_
54-12	5639-5642	the	abstract[336]|abstract[337]|place[338]|abstract[339]	new[336]|new[337]|new[338]|giv[339]	_	_
54-13	5643-5648	tumor	abstract[336]|abstract[337]|place[338]|abstract[339]	new[336]|new[337]|new[338]|giv[339]	_	_
54-14	5649-5657	directly	abstract[336]|abstract[337]|place[338]|abstract[339]	new[336]|new[337]|new[338]|giv[339]	_	_
54-15	5658-5660	or	_	_	_	_
54-16	5661-5668	through	_	_	_	_
54-17	5669-5681	intermediate	abstract[340]	new[340]	_	_
54-18	5682-5691	mediators	abstract[340]	new[340]	_	_
54-19	5692-5696	such	abstract[340]	new[340]	_	_
54-20	5697-5699	as	abstract[340]	new[340]	_	_
54-21	5700-5703	uPA	abstract[340]|substance	new[340]|giv	_	_
54-22	5704-5705	,	abstract[340]	new[340]	_	_
54-23	5706-5710	MMPs	abstract[340]|object	new[340]|giv	_	_
54-24	5711-5712	,	abstract[340]	new[340]	_	_
54-25	5713-5715	or	abstract[340]	new[340]	_	_
54-26	5716-5723	plasmin	abstract[340]|object	new[340]|new	_	_
54-27	5724-5725	.	_	_	_	_
